Should You Buy Sangamo Therapeutics Inc (SGMO) Today? Analysis, Price Targets, and 2026 Outlook.
No data
No data
Growth
Profitability
Efficiency
Wall Street analysts forecast SGMO.O stock price to rise
4 Analyst Rating
Wall Street analysts forecast SGMO.O stock price to rise
1 Buy
3 Hold
0 Sell
Hold
Current: 0.178
Low
1
Averages
3.75
High
10
Current: 0.178
Low
1
Averages
3.75
High
10
H.C. Wainwright
Patrick Trucchio
Buy
downgrade
$10 -> $5
AI Analysis
2026-05-26
New
Reason
H.C. Wainwright
Patrick Trucchio
Price Target
$10 -> $5
AI Analysis
2026-05-26
New
downgrade
Buy
Reason
H.C. Wainwright analyst Patrick Trucchio lowered the firm's price target on Sangamo to $5 from $10 and keeps a Buy rating on the shares. While stating that its regulatory and clinical thesis for isaralgagene civaparvovec in Fabry disease remains intact, the firm is lowering its price target to reflect the uncertainty of securing a commercialization partner or the funding to continue operations through the final steps of the Fabry rolling biologics license application filing while supporting the advancement of its neurology pipeline.
Barclays
Overweight -> Equal Weight
downgrade
$5 -> $1
2025-11-07
Reason
Barclays
Price Target
$5 -> $1
2025-11-07
downgrade
Overweight -> Equal Weight
Reason
Barclays downgraded Sangamo to Equal Weight from Overweight with a price target of $1, down from $5. The company's Q3 report highlighted the FDA's reaffirmation of an accelerated approval path using eGFR slope as the endpoint and its cash runway has been extended into Q1 of 2026, the analyst tells investors in a research note. Barclays steps to the sidelines pending further clarity on a Fabry deal.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SGMO.O
